eCQM Title

Initiation and Engagement of Substance Use Disorder Treatment

CMS ID

137

eCQM Version Number

15.0.000

CBE Number

Not Applicable

GUID

c3657d72-21b4-4675-820a-86c7fe293bf5

Measurement Period

January 1, 2027 through December 31, 2027

Measure Steward

National Committee for Quality Assurance

Measure Developer

National Committee for Quality Assurance

Endorsed By

None

Description

Percentage of patients 13 years of age and older with a new substance use disorder (SUD) episode who received the following (Two rates are reported):

a. Percentage of patients who initiated treatment, including either an intervention or medication for the treatment of SUD, within 14 days of the new SUD episode.

b. Percentage of patients who engaged in ongoing treatment, including two additional interventions or medication treatment events for SUD, or one long-acting medication event for the treatment of SUD, within 34 days of the initiation.

This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of the measure or specification. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure may be used for internal, noncommercial purposes (e.g., use by healthcare providers in connection with their practices) without obtaining approval from NCQA. All other uses, including a commercial use (including but not limited to vendors using or embedding the measures and specifications into any product or service to calculate measure results for customers for any purpose), must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2026 National Committee for Quality Assurance. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third-party codes contained in the specifications.

CPT (R) only Copyright 2025 American Medical Association. All rights Reserved. No fee schedules, basic unit, relative values or related listings are included in CPT (R). AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for data contained herein.

This material contains content from LOINC (http://loinc.org). LOINC is copyright (C) Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee and is available at no cost under the license at http://loinc.org/license. LOINC (R) is a registered United States trademark of Regenstrief Institute, Inc.

This material includes SNOMED Clinical Terms (R) (SNOMED CT [R]) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO). All rights reserved. SNOMED CT (R), was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

Some measures use RxNorm, a standardized nomenclature and coding for clinical drugs and drug delivery devices, which is made publicly available courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services. NLM is not responsible for the measures and does not endorse or recommend this or any other product.

“HL7” is the registered trademark of Health Level Seven International.

Disclaimer

The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].

Measure Scoring

Proportion

Measure Type

Process

Stratification

Report a total score, and each of the following strata:

Stratum 1: Patients age 13-17 at the start of the measurement period

Stratum 2: Patients age 18-64 at the start of the measurement period

Stratum 3: Patients age 65 and older at the start of the measurement period

Risk Adjustment

None

Rate Aggregation

None

Rationale

There are more deaths, illnesses and disabilities from substance abuse than from any other preventable health condition. In 2021, 46.3 million individuals in the U.S. age 12 or older (16.5 percent of the population) met the diagnosis criteria for having an SUD within the past year (Substance Abuse and Mental Health Services Administration [SAMHSA], 2022). Despite the high prevalence of SUD in the U.S., 94 percent of individuals aged 12 or older with an SUD did not receive any treatment (SAMHSA, 2022).

Clinical Recommendation Statement

American Society of Addiction Medicine (2020)

All Food and Drug Administration approved medications for the treatment of opioid use disorder should be available to all patients. Clinicians should consider the patient’s preferences, past treatment history, current state of illness, and treatment setting when deciding between the use of methadone, buprenorphine, and naltrexone.
There is no recommended time limit for pharmacological treatment
Patients’ psychosocial needs should be assessed, and patients should be offered or referred to psychosocial treatment based on their individual needs. However, a patient’s decision to decline psychosocial treatment or the absence of available psychosocial treatment should not preclude or delay pharmacotherapy, with appropriate medication management. Motivational interviewing or enhancement can be used to encourage patients to engage in psychosocial treatment services appropriate for addressing individual needs.

American Psychiatric Association (2018)

Patients with alcohol use disorder should have a documented comprehensive and person-centered treatment plan that includes evidence-based nonpharmacological and pharmacological treatments. [1C]
Naltrexone or acamprosate should be offered to patients with moderate to severe alcohol use disorder who have a goal of reducing alcohol consumption or achieving abstinence, prefer pharmacotherapy or have not responded to nonpharmacological treatments alone, and have no contraindications to the use of these medications. [1B]
Disulfiram should be offered to patients with moderate to severe alcohol use disorder who have a goal of achieving abstinence, prefer disulfiram or are intolerant to or have not responded to naltrexone and acamprosate, are capable of understanding the risks of alcohol consumption while taking disulfiram, and have no contraindications to the use of this medication. [2C]
Topiramate or gabapentin should be offered to patients with moderate to severe alcohol use disorder who have a goal of reducing alcohol consumption or achieving abstinence, prefer topiramate or gabapentin or are intolerant to or have not responded to naltrexone and acamprosate, and have no contraindications to the use of these medications. [2C]

American Psychiatric Association (2006)

Because many substance use disorders are chronic, patients usually require long-term treatment, although the intensity and specific components of treatment may vary over time [I rating].
It is important to intensify the monitoring for substance use during periods when the patient is at a high risk of relapsing, including during the early stages of treatment, times of transition to less intensive levels of care, and the first year after active treatment has ceased [I rating].
Outpatient treatment of substance use disorders is appropriate for patients whose clinical condition or environmental circumstances do not require a more intensive level of care [I rating]. As in other treatment settings, a comprehensive approach is optimal, using, where indicated, a variety of psychotherapeutic and pharmacological interventions along with behavioral monitoring [I rating].
Disulfiram is also recommended for patients with alcohol dependence [II rating].
Naltrexone, injectable naltrexone, acamprosate, a y-aminobutyric acid (GABA) are recommended for patients with alcohol dependence [I rating]. Disulfiram is also recommended for patients with alcohol dependence [II rating].
Methadone and buprenorphine are recommended for patients with opioid dependence [I rating].
Naltrexone is an alternative strategy [I rating].

American Society of Addiction Medicine (2015)

Methadone and buprenorphine are recommended for opioid use disorder treatment and withdrawal management.
Naltrexone (oral; extended-release injectable) is recommended for relapse prevention.

Michigan Quality Improvement Consortium (2021)

Patients with substance use disorder or risky substance use: Patient Education and Brief Intervention by a Primary Care Physician (PCP) or Trained Staff (e.g., Registered Nurse [RN], Master of Social Work [MSW])
If diagnosed with substance use disorder or risky substance use, initiate an intervention within 14 days.
Frequent follow-up is helpful to support behavior change; preferably 2 visits within 30 days.
Refer to a substance abuse health specialist, an addiction physician specialist, or a physician experienced in pharmacologic management of addiction.

Department of Veterans Affairs/Department of Defense (2015)

Offer referral to specialty SUD care for addiction treatment based on willingness to engage. [B]
For patients with moderate-severe alcohol use disorder, we recommend: Acamprosate, Disulfiram, Naltrexone- oral or extended release, or Topiramate. [A]
Medications should be offered in combined with addiction-focused counseling, offering one or more of the following interventions considering patient preference and provider training/competence: Behavioral Couples Therapy for alcohol use disorder, Cognitive Behavioral Therapy for substance use disorders, Community Reinforcement Approach, Motivational Enhancement Therapy, 12-Step Facilitation. [A]
For patients with opioid use disorder we recommend buprenorphine/naloxone or methadone in an Opioid Treatment Program. For patients for whom agonist treatment is contraindicated, unacceptable, unavailable, or discontinued, we recommend extended-release injectable naltrexone. [A]
For patients initiated in an intensive phase of outpatient or residential treatment, recommend ongoing systematic relapse prevention efforts or recovery support, individualized on the basis of treatment response. [A]

Improvement Notation

Higher score indicates better quality

Reference

Reference Type: Citation

Reference Text:

American Psychiatric Association, Kleber, H. D., & McIntyre, J. S. (2006). Practice Guideline for Treatment of Patients with Substance Use Disorders (pp. 1-276). Arlington, VA: American Psychiatric Association.

Reference

Reference Type: Citation

Reference Text:

American Society of Addiction Medicine (ASAM). (2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.

Reference

Reference Type: Citation

Reference Text:

Department of Veteran Affairs, Department of Defense. (2015). VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington DC: Department of Veterans Affairs, Department of Defense.

Reference

Reference Type: Citation

Reference Text:

Kampman, K., Jarvis, M. (2015). The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of Addiction Medicine; 9(5), 358–367. https://doi.org/10.1097/ADM.0000000000000166

Reference

Reference Type: Citation

Reference Text:

Michigan Quality Improvement Consortium. (2021). Screening, Diagnosis and Referral for Substance Use Disorders. Southfield, (MI): Michigan Quality Improvement Consortium. Retrieved from https://www.improve.health/wp-content/uploads/2023/04/mqicscreeningdiagnosisandreferralforsubstanceusedisordersFINAL-1.pdf

Reference

Reference Type: Citation

Reference Text:

Reus, V. et al. (2018). Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder. American Journal of Psychiatry, 175(1), 86-90. https://doi.org/10.1176/appi.ajp.2017.1750101

Reference

Reference Type: Citation

Reference Text:

Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report

Definition

The new SUD episode is the first encounter during the Intake Period with a diagnosis of SUD with no encounter or medication treatment for a diagnosis of SUD in the 60 days prior.

The initiation of treatment is the first SUD treatment within 14 days of a new SUD episode.

Treatment includes inpatient SUD admissions, outpatient visits, intensive outpatient encounters or partial hospitalizations, and medications for the treatment of SUD.

The Intake Period: January 1-November 14 of the measurement year. The Intake Period is used to capture new SUD episodes. The November 14 cut-off date ensures that all services can occur before the measurement period ends.

Guidance

This eCQM is a patient-based measure.

This version of the eCQM uses QDM version 5.6. Please refer to the eCQI resource center (https://ecqi.healthit.gov/qdm) for more information on the QDM.

Transmission Format

TBD

Initial Population

Patients 13 years of age and older as of the start of the measurement period who were diagnosed with a new SUD episode during a visit between January 1 and November 14 of the measurement period

Denominator

Equals Initial Population

Denominator Exclusions

Exclude patients who are in hospice care for any part of the measurement period

Numerator

Numerator 1: Initiation of treatment includes either an intervention or medication for the treatment of SUD within 14 days of the new SUD episode.

Numerator 2: Engagement in ongoing SUD treatment within 34 days of initiation includes:

A long-acting SUD medication on the day after the initiation through 34 days after the initiation of treatment.
One of the following options on the day after the initiation of treatment through 34 days after the initiation of treatment: a) two engagement visits, b) two engagement medication treatment events, c) one engagement visit and one engagement medication treatment event.

Numerator Exclusions

None

Denominator Exceptions

None

Supplemental Data Elements

For every patient evaluated by this measure also identify payer, race, ethnicity and sex

Population Criteria
Definitions
Functions
Terminology
Data Criteria (QDM Data Elements)
Supplemental Data Elements
Risk Adjustment Variables

Population Criteria

Definitions

Denominator
- - "Initial Population"

Denominator Exclusions
- - Hospice."Has Hospice Services"

Emergency Department or Detoxification Visit

  ["Encounter, Performed": "Emergency Department Evaluation and Management Visit"]
    union ["Encounter, Performed": "Detoxification Visit"]

First SUD Episode During Measurement Period

  First(("Qualifying Encounters") ValidEncounters
      with ["Diagnosis": "Substance Use Disorder"] SUDDiagnosis
        such that ValidEncounters.relevantPeriod during "Measurement Period"
          and SUDDiagnosis.prevalencePeriod starts during ValidEncounters.relevantPeriod
          and SUDDiagnosis.prevalencePeriod starts 47 days or more before day of 
          end of "Measurement Period"
      sort by start of relevantPeriod
  )

Has Treatment Engagement With Long Acting Medication

  exists ( ( ["Medication, Order": "Substance Use Disorder Long Acting Medication"] LongActingMedOrder
        with ( Min("Treatment Initiation With Non Medication Intervention Dates"
            union "Treatment Initiation With Medication Order Dates"
        ) ) InitiationTreatmentDate
          such that date from LongActingMedOrder.authorDatetime 34 days or less after InitiationTreatmentDate
    )
      union ( ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"] LongActingTreatment
          with ( Min("Treatment Initiation With Non Medication Intervention Dates"
              union "Treatment Initiation With Medication Order Dates"
          ) ) InitiationTreatmentDate
            such that date from start of Global."NormalizeInterval" ( LongActingTreatment.relevantDatetime, LongActingTreatment.relevantPeriod ) 34 days or less after InitiationTreatmentDate
      )
  )

Has Two or More Treatment Engagements With Short Acting Medication or Non Medication Intervention

  Count((("Psychosocial Visit"
        union ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"]) ShortActingTreatment
        with(Min("Treatment Initiation With Non Medication Intervention Dates"
            union "Treatment Initiation With Medication Order Dates"
        )) InitiationTreatmentDate
          such that date from start of Global."NormalizeInterval"(ShortActingTreatment.relevantDatetime, ShortActingTreatment.relevantPeriod) 34 days or less after InitiationTreatmentDate
        return all ShortActingTreatment
    )
      union(["Medication, Order": "Substance Use Disorder Short Acting Medication"] ShortActingMedOrder
          with(Min("Treatment Initiation With Non Medication Intervention Dates"
              union "Treatment Initiation With Medication Order Dates"
          )) InitiationTreatmentDate
            such that date from ShortActingMedOrder.authorDatetime 34 days or less after InitiationTreatmentDate
          return all ShortActingMedOrder
      )
  ) >= 2

History of SUD Diagnosis or Treatment

  ( ( ["Intervention, Performed": "Substance Use Disorder Treatment"]
      union ["Intervention, Performed": "Psych Visit Psychotherapy"]
      union ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"]
      union ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"] ) Interventions
      with "First SUD Episode During Measurement Period" FirstSUDEpisode
        such that Global."NormalizeInterval" ( Interventions.relevantDatetime, Interventions.relevantPeriod ) starts 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
  )
    union ( ( ( "Qualifying Encounters"
        except "Emergency Department or Detoxification Visit" ) QualifyingEncounter
        where ( exists QualifyingEncounter.diagnoses Diagnosis
            where Diagnosis.code in "Substance Use Disorder"
        ) ) EncounterWithDiagnosis
        with "First SUD Episode During Measurement Period" FirstSUDEpisode
          such that EncounterWithDiagnosis.relevantPeriod starts 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
    )
    union ( ( ["Medication, Order": "Substance Use Disorder Long Acting Medication"]
        union ["Medication, Order": "Substance Use Disorder Short Acting Medication"] ) SUDMedication
        with "First SUD Episode During Measurement Period" FirstSUDEpisode
          such that SUDMedication.authorDatetime 60 days or less before day of start of FirstSUDEpisode.relevantPeriod
    )

Hospice.Has Hospice Services

  exists ( ["Encounter, Performed": "Encounter Inpatient"] InpatientEncounter
      where ( InpatientEncounter.dischargeDisposition ~ "Discharge to home for hospice care (procedure)"
          or InpatientEncounter.dischargeDisposition ~ "Discharge to healthcare facility for hospice care (procedure)"
      )
        and InpatientEncounter.relevantPeriod ends during day of "Measurement Period"
  )
    or exists ( ["Encounter, Performed": "Hospice Encounter"] HospiceEncounter
        where HospiceEncounter.relevantPeriod overlaps day of "Measurement Period"
    )
    or exists ( ["Assessment, Performed": "Hospice care [Minimum Data Set]"] HospiceAssessment
        where HospiceAssessment.result ~ "Yes (qualifier value)"
          and Global."NormalizeInterval" ( HospiceAssessment.relevantDatetime, HospiceAssessment.relevantPeriod ) overlaps day of "Measurement Period"
    )
    or exists ( ["Intervention, Order": "Hospice Care Ambulatory"] HospiceOrder
        where HospiceOrder.authorDatetime during day of "Measurement Period"
    )
    or exists ( ["Intervention, Performed": "Hospice Care Ambulatory"] HospicePerformed
        where Global."NormalizeInterval" ( HospicePerformed.relevantDatetime, HospicePerformed.relevantPeriod ) overlaps day of "Measurement Period"
    )
  or exists ( ["Diagnosis": "Hospice Diagnosis"] HospiceCareDiagnosis
        where HospiceCareDiagnosis.prevalencePeriod overlaps day of "Measurement Period"
    )

Initial Population

  AgeInYearsAt(date from start of "Measurement Period") >= 13
    and "First SUD Episode During Measurement Period" is not null
    and not exists "History of SUD Diagnosis or Treatment"

Numerator 1

  exists "Treatment Initiation With Non Medication Intervention Dates"
    or exists "Treatment Initiation With Medication Order Dates"

Numerator 2

  "Has Treatment Engagement With Long Acting Medication"
    or "Has Two or More Treatment Engagements With Short Acting Medication or Non Medication Intervention"

Psychosocial Visit

  ["Intervention, Performed": "Substance Use Disorder Treatment"]
    union ["Intervention, Performed": "Psych Visit Psychotherapy"]
    union ( ( ["Encounter, Performed": "Telephone Visits"]
        union ["Encounter, Performed": "Virtual Encounter"] ) TelehealthEncounter
        where exists TelehealthEncounter.diagnoses Diagnosis
          where Diagnosis.code in "Substance Use Disorder"
    )

Qualifying Encounters

  ( ["Encounter, Performed": "Office Visit"]
      union ["Encounter, Performed": "Emergency Department Evaluation and Management Visit"]
      union ["Encounter, Performed": "Detoxification Visit"]
      union ["Encounter, Performed": "Initial Hospital Inpatient Visit"]
      union ["Encounter, Performed": "Discharge Services Hospital Inpatient Same Day Discharge"]
      union ["Encounter, Performed": "Discharge Services Hospital Inpatient"]
      union ["Encounter, Performed": "Telephone Visits"]
      union ["Encounter, Performed": "Virtual Encounter"]
  )

SDE Ethnicity

  ["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

  ["Patient Characteristic Payer": "Payer Type"]

SDE Race

  ["Patient Characteristic Race": "Race"]

SDE Sex

  ["Patient Characteristic Sex": "Federal Administrative Sex"]

Stratification 1

  AgeInYearsAt(date from start of "Measurement Period") in Interval[13, 17]

Stratification 2

  AgeInYearsAt(date from start of "Measurement Period") in Interval[18, 64]

Stratification 3

  AgeInYearsAt(date from start of "Measurement Period") >= 65

Treatment Initiation With Medication Order Dates

  ( ( ["Medication, Order": "Substance Use Disorder Short Acting Medication"]
      union ["Medication, Order": "Substance Use Disorder Long Acting Medication"] ) SUDMedication
      let treatmentDate: date from SUDMedication.authorDatetime
      with "First SUD Episode During Measurement Period" FirstSUDEpisode
        such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
      return all treatmentDate
  )
    union ( ( ["Procedure, Performed": "Substance Use Disorder Short Acting Medication Administration"]
        union ["Procedure, Performed": "Substance Use Disorder Long Acting Medication Administration"] ) SUDMedAdministration
        let treatmentDate: date from start of Global."NormalizeInterval" ( SUDMedAdministration.relevantDatetime, SUDMedAdministration.relevantPeriod )
        with "First SUD Episode During Measurement Period" FirstSUDEpisode
          such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
        return all treatmentDate
    )

Treatment Initiation With Non Medication Intervention Dates

  "Psychosocial Visit" PsychosocialVisit
    let treatmentDate: date from start of Global."NormalizeInterval" ( PsychosocialVisit.relevantDatetime, PsychosocialVisit.relevantPeriod )
    with "First SUD Episode During Measurement Period" FirstSUDEpisode
      such that treatmentDate during Interval[date from start of FirstSUDEpisode.relevantPeriod, date from start of FirstSUDEpisode.relevantPeriod + 14 days )
        and PsychosocialVisit.id != FirstSUDEpisode.id
    return all treatmentDate

Functions

Global.NormalizeInterval(pointInTime DateTime, period Interval<DateTime>)

  if pointInTime is not null then Interval[pointInTime, pointInTime]
    else if period is not null then period 
    else null as Interval<DateTime>

Terminology

code "Discharge to healthcare facility for hospice care (procedure)" ("SNOMEDCT Code (428371000124100)")
code "Discharge to home for hospice care (procedure)" ("SNOMEDCT Code (428361000124107)")
code "Hospice care [Minimum Data Set]" ("LOINC Code (45755-6)")
code "Yes (qualifier value)" ("SNOMEDCT Code (373066001)")
valueset "Detoxification Visit" (2.16.840.1.113883.3.464.1003.101.12.1059)
valueset "Discharge Services Hospital Inpatient" (2.16.840.1.113883.3.464.1003.101.12.1007)
valueset "Discharge Services Hospital Inpatient Same Day Discharge" (2.16.840.1.113883.3.464.1003.101.12.1006)
valueset "Emergency Department Evaluation and Management Visit" (2.16.840.1.113883.3.464.1003.101.12.1010)
valueset "Encounter Inpatient" (2.16.840.1.113883.3.666.5.307)
valueset "Ethnicity" (2.16.840.1.114222.4.11.837)
valueset "Federal Administrative Sex" (2.16.840.1.113762.1.4.1021.121)
valueset "Hospice Care Ambulatory" (2.16.840.1.113883.3.526.3.1584)
valueset "Hospice Diagnosis" (2.16.840.1.113883.3.464.1003.1165)
valueset "Hospice Encounter" (2.16.840.1.113883.3.464.1003.1003)
valueset "Initial Hospital Inpatient Visit" (2.16.840.1.113883.3.464.1003.101.12.1004)
valueset "Office Visit" (2.16.840.1.113883.3.464.1003.101.12.1001)
valueset "Payer Type" (2.16.840.1.114222.4.11.3591)
valueset "Psych Visit Psychotherapy" (2.16.840.1.113883.3.526.3.1496)
valueset "Race" (2.16.840.1.114222.4.11.836)
valueset "Substance Use Disorder" (2.16.840.1.113883.3.464.1003.106.12.1001)
valueset "Substance Use Disorder Long Acting Medication" (2.16.840.1.113883.3.464.1003.1149)
valueset "Substance Use Disorder Long Acting Medication Administration" (2.16.840.1.113883.3.464.1003.1156)
valueset "Substance Use Disorder Short Acting Medication" (2.16.840.1.113883.3.464.1003.1150)
valueset "Substance Use Disorder Short Acting Medication Administration" (2.16.840.1.113883.3.464.1003.1157)
valueset "Substance Use Disorder Treatment" (2.16.840.1.113883.3.464.1003.106.12.1005)
valueset "Telephone Visits" (2.16.840.1.113883.3.464.1003.101.12.1080)
valueset "Virtual Encounter" (2.16.840.1.113883.3.464.1003.101.12.1089)

Data Criteria (QDM Data Elements)

"Assessment, Performed: Hospice care [Minimum Data Set]" using "Hospice care [Minimum Data Set] (LOINC Code 45755-6)"
"Diagnosis: Hospice Diagnosis" using "Hospice Diagnosis (2.16.840.1.113883.3.464.1003.1165)"
"Diagnosis: Substance Use Disorder" using "Substance Use Disorder (2.16.840.1.113883.3.464.1003.106.12.1001)"
"Encounter, Performed: Detoxification Visit" using "Detoxification Visit (2.16.840.1.113883.3.464.1003.101.12.1059)"
"Encounter, Performed: Discharge Services Hospital Inpatient Same Day Discharge" using "Discharge Services Hospital Inpatient Same Day Discharge (2.16.840.1.113883.3.464.1003.101.12.1006)"
"Encounter, Performed: Discharge Services Hospital Inpatient" using "Discharge Services Hospital Inpatient (2.16.840.1.113883.3.464.1003.101.12.1007)"
"Encounter, Performed: Emergency Department Evaluation and Management Visit" using "Emergency Department Evaluation and Management Visit (2.16.840.1.113883.3.464.1003.101.12.1010)"
"Encounter, Performed: Encounter Inpatient" using "Encounter Inpatient (2.16.840.1.113883.3.666.5.307)"
"Encounter, Performed: Hospice Encounter" using "Hospice Encounter (2.16.840.1.113883.3.464.1003.1003)"
"Encounter, Performed: Initial Hospital Inpatient Visit" using "Initial Hospital Inpatient Visit (2.16.840.1.113883.3.464.1003.101.12.1004)"
"Encounter, Performed: Office Visit" using "Office Visit (2.16.840.1.113883.3.464.1003.101.12.1001)"
"Encounter, Performed: Telephone Visits" using "Telephone Visits (2.16.840.1.113883.3.464.1003.101.12.1080)"
"Encounter, Performed: Virtual Encounter" using "Virtual Encounter (2.16.840.1.113883.3.464.1003.101.12.1089)"
"Intervention, Order: Hospice Care Ambulatory" using "Hospice Care Ambulatory (2.16.840.1.113883.3.526.3.1584)"
"Intervention, Performed: Hospice Care Ambulatory" using "Hospice Care Ambulatory (2.16.840.1.113883.3.526.3.1584)"
"Intervention, Performed: Psych Visit Psychotherapy" using "Psych Visit Psychotherapy (2.16.840.1.113883.3.526.3.1496)"
"Intervention, Performed: Substance Use Disorder Treatment" using "Substance Use Disorder Treatment (2.16.840.1.113883.3.464.1003.106.12.1005)"
"Medication, Order: Substance Use Disorder Long Acting Medication" using "Substance Use Disorder Long Acting Medication (2.16.840.1.113883.3.464.1003.1149)"
"Medication, Order: Substance Use Disorder Short Acting Medication" using "Substance Use Disorder Short Acting Medication (2.16.840.1.113883.3.464.1003.1150)"
"Patient Characteristic Ethnicity: Ethnicity" using "Ethnicity (2.16.840.1.114222.4.11.837)"
"Patient Characteristic Payer: Payer Type" using "Payer Type (2.16.840.1.114222.4.11.3591)"
"Patient Characteristic Race: Race" using "Race (2.16.840.1.114222.4.11.836)"
"Patient Characteristic Sex: Federal Administrative Sex" using "Federal Administrative Sex (2.16.840.1.113762.1.4.1021.121)"
"Procedure, Performed: Substance Use Disorder Long Acting Medication Administration" using "Substance Use Disorder Long Acting Medication Administration (2.16.840.1.113883.3.464.1003.1156)"
"Procedure, Performed: Substance Use Disorder Short Acting Medication Administration" using "Substance Use Disorder Short Acting Medication Administration (2.16.840.1.113883.3.464.1003.1157)"

Supplemental Data Elements

SDE Ethnicity

  ["Patient Characteristic Ethnicity": "Ethnicity"]

SDE Payer

  ["Patient Characteristic Payer": "Payer Type"]

SDE Race

  ["Patient Characteristic Race": "Race"]

SDE Sex

  ["Patient Characteristic Sex": "Federal Administrative Sex"]

Risk Adjustment Variables

None

Measure Set

None